Martin Dietrich, MD, PhD, discusses how the FDA-approved combination therapy is transforming care for resectable early-stage ...

Lenalidomide improved upon the efficacy of durvalumab in patients with refractory or advanced CTCL in a phase 1/2 trial.

Consolidation durvalumab is underutilized in unresectable stage III NSCLC, with only 61.5% of eligible patients receiving it post-cCRT. Patients receiving durvalumab after cCRT show improved ...

Immune-mediated rash or dermatitis occurred in 1.8% (34/ ... Europe and Asia. IMFINZI ® (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction ...

For patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) with a contraindication for cis ...

If approved, durvalumab will be the first and only perioperative immunotherapy regimen available for the treatment of ...

However, there is currently no consensus on the standard of care for this population. Durvalumab, an immune checkpoint inhibitor, has shown promise for treating a wide range of cancers, and has been ...

Durvalumab was associated with a 27% reduction in the risk for death compared with placebo in the phase 3 ADRIATIC trial.

Immune-mediated rash or dermatitis occurred in 1.8% (34/1889 ... The safety and effectiveness of IMFINZI has not been established in pediatric patients. IMFINZI® (durvalumab), as a single ...

IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer Based on ADRIATIC Phase III trial results which showed a 27 ...

AstraZeneca’s IMFINZI ® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following ...